Search

EHA Ranking 2025

The information on this page is also available as a printable PDF. EHA Ranking 2025 — PDF version

Position
Company
Priority points
Corporate Level

1
Johnson & Johnson 
1. 488,82 
Platinum 

2
Bristol Myers Squibb 
1.

Corporate Sponsor Program

View the EHA Ranking 2025

"Alone we can do so little; together we can do so much.

Registration & Accommodation

Registration is now closed. Registration fee includes:

Access to the scientific and educational sessions of the meeting
Networking opportunities during breaks and welcome reception
Catering during meeting hours incl.

How to apply

The CRTH 2025 call for applications is now closed. Timelines
Application CRTH 2025
Deadline: September 24, 2024 (15:00 CEST)

Notification
November 2024

Questions: training@ehaweb. orgDownload the Signature letter template.

Adolescents and young adults (AYA)

Spotlight on AYAAdolescents and young adults (AYA) with hematologic diseases are a unique group with special characteristics and needs. In recent years, the challenges related to the management of AYA (particularly in relation to cancer) have increasingly been recognized.

Regulatory affairs & scientific relations

EHA’s regulatory work: European Medicines AgencyMost of EHA’s regulatory work entails collaboration with the European Medicines Agency (EMA).

Alliances & partnerships

EHA's approach to policy and regulatory affairs involves collaboration across medical professions and disciplines.

SPC Advisory Board, EHA2025 Congress

Current committee members
Lorena Arranz, Norway
Peter Borchmann, Germany
Veronika Buxhofer-Ausch, Austria
Ana Cvejic, Denmark
Matteo Della Porta, Italy
Michael Doubek, Czechia
Andreas Glenthøj, Denmark
Maria Gomes da Silva, Portugal
Julia Hauer, Germany
Daniel Hodson, United Kingdom
Cristina João, Portugal
Sören Lehmann, Sweden
Tamás Masszi, Hungary
Karinna Meijer, The Netherlands
Jamie O'Sullivan, Ireland
Cristina Papayannidis, Italy
France…

Substances of Human Origin (SoHO) legislation

EHA’s involvementEHA has been involved in both the evaluation and subsequent revision of the EU legislation on human blood and blood components. The evaluation of these rules, which dated back to 2002, began in 2016.